427 research outputs found
Supplemental Material, Appendix1_Ethics_committee_071618 - The Treatment Intensity of Anticoagulant Therapy for Patients With Sepsis-Induced Disseminated Intravascular Coagulation and Outcomes: A Multicenter Cohort Study
No full textSupplemental Material, Appendix1_Ethics_committee_071618 for The Treatment Intensity of Anticoagulant Therapy for Patients With Sepsis-Induced Disseminated Intravascular Coagulation and Outcomes: A Multicenter Cohort Study by Daisuke Kudo, Mineji Hayakawa, Hiroaki Iijima, Kazuma Yamakawa, Shinjiro Saito, Shigehiko Uchino, Yusuke Iizuka, Masamitsu Sanui, Kohei Takimoto, Toshihiko Mayumi, and JSEPTIC DIC Study Investigators in Clinical and Applied Thrombosis/Hemostasis</p
Supplemental Material, Supplemental_figure_1 - The Treatment Intensity of Anticoagulant Therapy for Patients With Sepsis-Induced Disseminated Intravascular Coagulation and Outcomes: A Multicenter Cohort Study
No full textSupplemental Material, Supplemental_figure_1 for The Treatment Intensity of Anticoagulant Therapy for Patients With Sepsis-Induced Disseminated Intravascular Coagulation and Outcomes: A Multicenter Cohort Study by Daisuke Kudo, Mineji Hayakawa, Hiroaki Iijima, Kazuma Yamakawa, Shinjiro Saito, Shigehiko Uchino, Yusuke Iizuka, Masamitsu Sanui, Kohei Takimoto, Toshihiko Mayumi, and JSEPTIC DIC Study Investigators in Clinical and Applied Thrombosis/Hemostasis</p
Supplemental Material, Supplemental_figure_3 - The Treatment Intensity of Anticoagulant Therapy for Patients With Sepsis-Induced Disseminated Intravascular Coagulation and Outcomes: A Multicenter Cohort Study
No full textSupplemental Material, Supplemental_figure_3 for The Treatment Intensity of Anticoagulant Therapy for Patients With Sepsis-Induced Disseminated Intravascular Coagulation and Outcomes: A Multicenter Cohort Study by Daisuke Kudo, Mineji Hayakawa, Hiroaki Iijima, Kazuma Yamakawa, Shinjiro Saito, Shigehiko Uchino, Yusuke Iizuka, Masamitsu Sanui, Kohei Takimoto, Toshihiko Mayumi, and JSEPTIC DIC Study Investigators in Clinical and Applied Thrombosis/Hemostasis</p
Supplemental Material, CATHAppendix2_List_authors_082418_(1) - The Treatment Intensity of Anticoagulant Therapy for Patients With Sepsis-Induced Disseminated Intravascular Coagulation and Outcomes: A Multicenter Cohort Study
No full textSupplemental Material, CATHAppendix2_List_authors_082418_(1) for The Treatment Intensity of Anticoagulant Therapy for Patients With Sepsis-Induced Disseminated Intravascular Coagulation and Outcomes: A Multicenter Cohort Study by Daisuke Kudo, Mineji Hayakawa, Hiroaki Iijima, Kazuma Yamakawa, Shinjiro Saito, Shigehiko Uchino, Yusuke Iizuka, Masamitsu Sanui, Kohei Takimoto, Toshihiko Mayumi, and JSEPTIC DIC Study Investigators in Clinical and Applied Thrombosis/Hemostasis</p
Supplemental Material, Suppl_figure_2_021519_(1) - The Treatment Intensity of Anticoagulant Therapy for Patients With Sepsis-Induced Disseminated Intravascular Coagulation and Outcomes: A Multicenter Cohort Study
No full textSupplemental Material, Suppl_figure_2_021519_(1) for The Treatment Intensity of Anticoagulant Therapy for Patients With Sepsis-Induced Disseminated Intravascular Coagulation and Outcomes: A Multicenter Cohort Study by Daisuke Kudo, Mineji Hayakawa, Hiroaki Iijima, Kazuma Yamakawa, Shinjiro Saito, Shigehiko Uchino, Yusuke Iizuka, Masamitsu Sanui, Kohei Takimoto, Toshihiko Mayumi, and JSEPTIC DIC Study Investigators in Clinical and Applied Thrombosis/Hemostasis</p
A total synthesis of spiruchostatin A
No full textWe achieved the total synthesis of the histone deacetylase inhibitor spiruchostatin A, as the prelude to the preparation of a combinatorial library of its analogues. Two key reactions were an asymmetric acetate aldol reaction using a Zr-enolate and macrolactonization Using the Shiina method
Risk Factors of Antiresorptive Agent-Related Osteonecrosis of the Jaw in Prostate Cancer Patients with Bone Metastases
No full textAntiresorptive agent-related osteonecrosis of the jaw (ARONJ) is a severe adverse event associated with use of bone resorption inhibitors (BRIs), such as zoledronic acid and denosumab. Based on the results of phase 3 clinical trials for BRIs, the frequency of ARONJ is reported to be 1 to 2%, but the actual frequency could be higher. We investigated 173 patients with prostate cancer with bone metastases who were treated either with zoledronic acid or denosumab at our hospital between July 2006 and June 2020. ARONJ occurred in 13 patients (8%); i.e., ten out of 159 patients (6%) who were treated with zoledronic acid, and three out of 14 patients (21%) who were treated with denosumab. Multivariate analysis showed that longer duration of BRI exposure and dental treatment before the initiation of BRI are associated with risk of ARONJ. ARONJ is associated with decreased mortality but the association is not significant. Generally, the occurrence of ARONJ may be underestimated; therefore, further studies are warranted to determine the actual frequency of ARONJ
Spin-splitting surface states of strained GaAs(001) and spontaneous spin current from breaking of twofold symmetry
No full textAbstractWe theoretically study the electronic structure and spin splitting of a strained GaAs(001) surface with broken twofold symmetry. We introduce a surface electron Hamiltonian of our model. By k·p theory, we qualitatively evaluate the electronic structure of GaAs(001) surface, demonstrating that the spin degeneracy of the bottom of the surface-state conduction bands is split. Additionally, by the spin current operator, we evaluate the spin current of electrons in the bottom of the surface-state conduction bands, demonstrating that for n-type GaAs the spin current flows in the parallel direction to a mirror plane spontaneously. This is a new mechanism to generate the spin current
Investigation of the Usefulness of Intermittent Self-Dilation after Transurethral Surgery for Urethral Stricture
No full textWe retrospectively examined the restenosis rate, factors associated withrestenosis withand without intermittent self-dilatation (ISD) after transurethral surgery for urethral stricture. Male patients diagnosed with urethral stricture between July 2012 and October 2019 who underwent primary treatment by internal urethrotomy or urethral stricture dilatation were divided into two groups : those who received ISD and those who did not. Factors associated with restenosis in the ISD group were also analyzed. The total number of patients analyzed was 45, 34 (75.6%) in the ISD group and 11 (24.4%) in the no ISD group. The median age was 71 years. 19 (42.2%) had undergone transurethral surgery, 15 (33.3%) had undergone total prostatectomy, and the majority had undergone urological surgery. The hazard ratio in the ISD group was 0.1894 (95% confidence interval : 0.06749-0.5317, p＝0.001), suggesting that ISD significantly increased the time to recurrence. ISD significantly prolonged the time to recurrence. Also, restenosis was significantly more frequent when ISD was performed for less than 5 months (p＝0.00723). The results suggest that intermittent self-dilation after transurethral surgery as primary treatment for urethral stricture significantly increases the time to restenosis and that performing the procedure for more than 5 months reduces the rate of restenosis development
- …
